for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Verastem Inc

VSTM.OQ

Latest Trade

1.90USD

Change

-0.07(-3.55%)

Volume

258,726

Today's Range

1.85

 - 

2.03

52 Week Range

0.83

 - 

3.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Verastem Oncology Announces Global Licensing Agreement With Chugai Pharmaceutical

Jan 8 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES GLOBAL LICENSING AGREEMENT WITH CHUGAI PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE RAF/MEK INHIBITOR CH5126766.VERASTEM INC - CO WILL MAKE AN UPFRONT PAYMENT OF $3M AND PAY ROYALTIES TO CHUGAI.VERASTEM INC - WILL BE EVALUATING VARIOUS PARTNERING STRATEGIES.VERASTEM - "WE PLAN TO INITIATE DISCUSSIONS WITH REGULATORY AUTHORITIES ABOUT OUR DEVELOPMENT PLANS AND TO DEFINE REGISTRATION PATH EARLY THIS YEAR".

Verastem's Phase 2 PRIMO Study Data Evaluating Duvelisib In Relapsed Or Refractory Peripheral T-Cell Lymphoma

Dec 7 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM - VERASTEM ONCOLOGY PRESENTS PHASE 2 PRIMO STUDY DATA EVALUATING DUVELISIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA.VERASTEM - DATA PRESENTED SUPPORT POTENTIAL OF DUVELISIB ACROSS INDICATIONS, LINES OF THERAPY AND IN COMBINATION.VERASTEM-DUVELISIB ACHIEVES RESPONSE RATE OF 62% IN PATIENTS WITH RELAPSED OR REFRACTORY PTCL WITH MANAGEABLE SAFETY PROFILE IN INITIAL PHASE OF PRIMO TRIAL.

Verastem Oncology Reports Third Quarter Loss Per Share Of $0.41

Oct 29 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT COMPANY PROGRESS.Q3 ADJUSTED NON-GAAP LOSS PER SHARE $0.35.Q3 LOSS PER SHARE $0.41.Q3 REVENUE $9.0 MILLION VERSUS REFINITIV IBES ESTIMATE OF $9 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA.REAFFIRMS FY2019 REVENUE GUIDANCE.COMPANY TO STREAMLINE ORGANIZATION AND REDUCE OPERATING EXPENSES BY $25 MILLION IN 2020.SEES ABOUT $1.0 MILLION IN PRE-TAX CHARGES FOR SEVERANCE, OTHER COSTS RELATED TO WORKFORCE REDUCTION.

Verastem Oncology Receives Orphan Drug Designation From FDA For Copiktra

Oct 3 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR COPIKTRA FOR THE TREATMENT OF T-CELL LYMPHOMA.VERASTEM INC - DUVELISIB (COPIKTRA) GOT ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR USE IN TREATMENT OF T-CELL LYMPHOMA.

Verastem Oncology Posts Q2 Loss Per Share Of $0.57

Aug 1 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS.Q2 ADJUSTED NON-GAAP LOSS PER SHARE $0.48.Q2 LOSS PER SHARE $0.57.Q2 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.RAISES PRODUCT REVENUE GUIDANCE FOR 2019.AS OF JUNE 30, 2019, VERASTEM ONCOLOGY HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $187.3 MILLION..EXPECTS 2019 NET PRODUCT REVENUE OF COPIKTRA TO BE IN RANGE OF $12-14 MILLION.QTRLY TOTAL REVENUE $3.1 MILLION VERSUS $10 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.50, REVENUE VIEW $2.3 MILLION -- REFINITIV IBES DATA.

Verastem Oncology Signs An Exclusive License Agreement With Sanofi

July 25 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH SANOFI FOR THE DEVELOPMENT AND COMMERCIALIZATION OF COPIKTRA® (DUVELISIB) IN RUSSIA AND CIS, TURKEY, THE MIDDLE EAST AND AFRICA.VERASTEM INC - ONCOLOGY SHALL RECEIVE AN UPFRONT PAYMENT OF $5 MILLION.VERASTEM INC - ELIGIBLE TO RECEIVE UP TO $42 MILLION USD IN DEVELOPMENT AND SALES MILESTONES AND DOUBLE-DIGIT PERCENTAGE ROYALTIES.VERASTEM INC - SANOFI OBTAINS RIGHTS TO DEVELOP AND COMMERCIALIZE COPIKTRA IN LICENSED TERRITORIES.

Verastem Oncology Announces Leadership Changes

June 20 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES LEADERSHIP CHANGES.CHIEF OPERATING OFFICER, DAN PATERSON APPOINTED PRESIDENT.ROBERT FORRESTER STEPPING DOWN FROM HIS ROLES AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.SAYS DAN PATERSON APPOINTED PRESIDENT.CHIEF FINANCIAL OFFICER, ROB GAGNON, EXPANDING ROLE TO INCLUDE CHIEF BUSINESS OFFICER.FORRESTER HAS AGREED TO CONTINUE SERVING VERASTEM ONCOLOGY IN AN ADVISORY CAPACITY..REITERATING ITS PREVIOUSLY ISSUED FINANCIAL GUIDANCE FOR FULL YEAR 2019.PATERSON WILL ASSUME LEADERSHIP OF EXECUTIVE TEAM WHILE BOARD OF DIRECTORS CONDUCTS A SEARCH TO IDENTIFY A SUCCESSOR.

Verastem Oncology Reports Q1 Loss Per Share $0.52

May 9 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE ESTIMATE $-0.47 -- REFINITIV IBES DATA.FOR 2019, THE COMPANY EXPECTS NET PRODUCT REVENUE FROM SALES OF COPIKTRA TO BE IN THE RANGE OF $10 MILLION -12 MILLION.

Verastem Inc Says 2019 Term Loan With Hercules Capital Will Mature On Dec 1, 2022

April 23 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM INC - 2019 TERM LOAN WITH HERCULES CAPITAL WILL MATURE ON DECEMBER 1, 2022.VERASTEM INC - 2019 TERM LOAN PROVIDES FOR INTEREST-ONLY PAYMENTS UNTIL APRIL 1, 2021, WHICH MAY BE EXTENDED TO DECEMBER 1, 2021.

Verastem Oncology Announces Amendment To Refinance Hercules Loan Facility

April 23 (Reuters) - Verastem Inc <VSTM.O>::VERASTEM ONCOLOGY ANNOUNCES AMENDMENT TO REFINANCE HERCULES LOAN FACILITY.VERASTEM INC - AMENDMENT INCREASES BORROWING LIMIT FROM $50 MILLION TO $75 MILLION IN FINANCING.VERASTEM INC - INCREASED LOAN FACILITY PROCEEDS WILL BE AVAILABLE FOR ONGOING LAUNCH OF COPIKTRA IN U.S..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up